<DOC>
	<DOCNO>NCT02025803</DOCNO>
	<brief_summary>The purpose exploratory study investigate safety determine maximum tolerate dose ( MTD ) TAS-114 combination capecitabine patient advance solid tumor patient available therapy likely convey clinical benefit .</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacokinetic Study TAS-114 Combination With Capecitabine Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>In animal model , co-administration TAS 114 capecitabine show antitumor effect exceed maximum efficacy obtain capecitabine alone . Developing novel chemotherapy base combine use TAS-114 capecitabine may fulfill need efficacious treatment patient advance solid tumor . The study , evaluate safety , tolerability , pharmacokinetics , preliminary antitumor activity TAS-114/ capecitabine regimen patient advance solid tumor , conduct two part : Dose-Escalation Phase ( Part 1 ) determine MTD ; Expansion Phase ( Part 2 ) evaluate safety preliminary efficacy MTD .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Provided write consent 2 . Is 18 year age old 3 . Has histologically cytologically confirm advanced , measurable nonmeasurable metastatic solid tumor patient available therapy convey clinical benefit Expansion Phase : The target population include least 1 . 12 patient breast cancer 5 FU chemotherapy standard treatment 2 . 28 patient refractory colorectal cancer . 4 . May receive prior therapy advance metastatic disease 5 . Expansion Phase : Has measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( Version 1.1 , 2009 ) , ie , least one measurable lesion 6 . Has ECOG performance status 0 1 Cycle 1 , Day 1 7 . Is able take medication orally 8 . Has adequate organ function define protocol 9 . Women childlbearing potential must negative pregnancy test within 7 day prior start study drug . Beth males female must agree adequate birth control conception possible study 6 month last dose 10 . Is willing able comply schedule visit study procedure . 1 . Has know DPD deficiency 2 . Has certain recent treatment e.g . major surgery , anticancer therapy , extend field radiation , receive investigational agent , within specified time frame prior study drug administration . 3 . Certain serious illness medical condition 4 . Is receive concomitant treatment drug may interact capecitabine 5 . Has prior gastrectomy 6 . Has know sensitivity capecitabine metabolites 7 . Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>